Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
A Marra, D Trapani, G Viale, C Criscitiello… - NPJ breast …, 2020 - nature.com
Triple-negative breast cancer (TNBC) is not a unique disease, encompassing multiple
entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite …
entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite …
Mitochondria as playmakers of apoptosis, autophagy and senescence
Mitochondria are the key energy-producing organelles and cellular source of reactive
species. They are responsible for managing cell life and death by a balanced homeostasis …
species. They are responsible for managing cell life and death by a balanced homeostasis …
Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial
PURPOSE The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently
activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown …
activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown …
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
O Martínez-Sáez, N Chic, T Pascual, B Adamo… - Breast cancer …, 2020 - Springer
Abstract Purpose The therascreen PIK3CA mutation assay and the alpha-specific PI3K
inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced …
inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced …
Brain metastasis
Brain metastasis, which commonly arises in patients with lung cancer, breast cancer and
melanoma, is associated with poor survival outcomes and poses distinct clinical challenges …
melanoma, is associated with poor survival outcomes and poses distinct clinical challenges …
The landscape of targeted therapies in TNBC
E Vagia, D Mahalingam, M Cristofanilli - Cancers, 2020 - mdpi.com
Triple negative breast cancer (TNBC) constitutes the most aggressive molecular subtype
among breast tumors. Despite progress on the underlying tumor biology, clinical outcomes …
among breast tumors. Despite progress on the underlying tumor biology, clinical outcomes …
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a
subgroup harboring evidence of defective homologous recombination (HR) DNA repair …
subgroup harboring evidence of defective homologous recombination (HR) DNA repair …
Multi-omics characterization of the 4T1 murine mammary gland tumor model
Background: Tumor models are critical for our understanding of cancer and the development
of cancer therapeutics. The 4T1 murine mammary cancer cell line is one of the most widely …
of cancer therapeutics. The 4T1 murine mammary cancer cell line is one of the most widely …
Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer
Despite decades of study, the molecular mechanisms and selectivity of the biomolecular
components of honeybee (Apis mellifera) venom as anticancer agents remain largely …
components of honeybee (Apis mellifera) venom as anticancer agents remain largely …
ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer
Mutations in ARID1A, a subunit of the SWI/SNF chromatin remodeling complex, are the most
common alterations of the SWI/SNF complex in estrogen-receptor-positive (ER+) breast …
common alterations of the SWI/SNF complex in estrogen-receptor-positive (ER+) breast …